Clinical Trials
16
Active:0
Completed:14
Trial Phases
3 Phases
Phase 3:1
Phase 4:12
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 4
12 (75.0%)Not Applicable
3 (18.8%)Phase 3
1 (6.3%)Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy
Phase 3
Terminated
- Conditions
- Asthma
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Mundipharma Korea Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT04124510
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment
Phase 4
Completed
- Conditions
- Low Back Pain
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Mundipharma Korea Ltd
- Target Recruit Count
- 123
- Registration Number
- NCT03768466
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Betafoam Diabetes Mellitus Foot Study
Not Applicable
Completed
- Conditions
- Diabetes MellitusFoot Ulcer
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Mundipharma Korea Ltd
- Target Recruit Count
- 71
- Registration Number
- NCT02732886
- Locations
- 🇰🇷
Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
Phase 4
Completed
- Conditions
- Cancer Pain
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Mundipharma Korea Ltd
- Target Recruit Count
- 66
- Registration Number
- NCT02660229
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
Burn Wound Management of Betafoam® and Allevyn® Ag
Not Applicable
Completed
- Conditions
- Acute Burn
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Mundipharma Korea Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT02660541
- Locations
- 🇰🇷
Hallym University Hangang Sacred Heart Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found